Intellia Therapeutics (NASDAQ:NTLA) Trading Up 8.8% – Still a Buy?

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) were up 8.8% during trading on Thursday . The stock traded as high as $13.89 and last traded at $14.1610. Approximately 561,798 shares traded hands during trading, a decline of 90% from the average daily volume of 5,390,905 shares. The stock had previously closed at $13.02.

Analyst Ratings Changes

Several analysts recently commented on NTLA shares. Sanford C. Bernstein increased their target price on shares of Intellia Therapeutics from $13.00 to $17.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. JonesTrading upgraded shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Wednesday, March 4th. Wells Fargo & Company increased their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday, March 3rd. Canaccord Genuity Group reduced their target price on Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Finally, Citigroup restated an “outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.25.

Intellia Therapeutics Stock Performance

The stock has a market cap of $2.09 billion, a price-to-earnings ratio of -4.20 and a beta of 1.92. The company’s 50 day simple moving average is $13.56 and its two-hundred day simple moving average is $12.09.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.11. The firm had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the prior year, the business earned ($1.10) EPS. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $30,000. Advisory Services Network LLC acquired a new position in Intellia Therapeutics in the 3rd quarter valued at approximately $33,000. Headlands Technologies LLC acquired a new position in Intellia Therapeutics in the 2nd quarter valued at approximately $26,000. Comerica Bank increased its stake in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares during the period. Finally, Danske Bank A S acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth $50,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.